Patents Examined by Delbert R. Phillips
  • Patent number: 4885277
    Abstract: A composition and method for treating thrombotic disorders. The composition comprises a peptide comprising an amino acid sequence corresponding to the sequence of the amino acid residues in the EGF domain of Factor IX, or a subsequence thereof. Such peptides compete with coagulation Factors IX and IXa for endothelial binding cites and thereby inhibit thrombosis formation.
    Type: Grant
    Filed: November 6, 1987
    Date of Patent: December 5, 1989
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Peter P. Nawroth, David M. Stern, George D. Wilner
  • Patent number: 4885276
    Abstract: New cyclosporin analogs with modified "C-9 amino acids" have been made and are found to be effective immunosuppressive agents.
    Type: Grant
    Filed: October 24, 1988
    Date of Patent: December 5, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Bruce E. Witzel
  • Patent number: 4882420
    Abstract: The present invention provides novel renin inhibitory peptides of the formula X--A--B--C--D--E--F--G--H--Z wherein E--F is a dihalo-substituted statine group, X and Z are terminal groups, and the remaining variables are absent or amino acid residues. These compounds are useful for administration to humans to treat hypertension.
    Type: Grant
    Filed: November 28, 1986
    Date of Patent: November 21, 1989
    Assignee: The Upjohn Company
    Inventor: Suvit Thaisrivongs
  • Patent number: 4880778
    Abstract: Disclosed are combinations of polypeptides acting in a synergistic manner to promote release and elevation of growth hormone levels in the blood of animals. Also disclosed are methods of promoting the release and elevation of growth hormone levels in the blood of animals using the disclosed combination of polypeptides.
    Type: Grant
    Filed: April 10, 1987
    Date of Patent: November 14, 1989
    Assignee: Eastman Kodak Company
    Inventors: Cyril Y. Bowers, Frank A. Momany, Ching H. Chang, Wayne Cody, John C. Hubbs, Charles H. Foster
  • Patent number: 4880781
    Abstract: The present invention provides novel renin-inhibiting peptides and novel processes and intermediates for the preparation of both novel and known renin-inhibiting peptide analogs. Such inhibitors are useful for the diagnosis and control of renin-dependent hypertension.
    Type: Grant
    Filed: January 20, 1988
    Date of Patent: November 14, 1989
    Assignee: The Upjohn Company
    Inventors: Jackson B. Hester, Jr., Suvit Thaisrivongs, Tomi K. Sawyer, Ruth E. TenBrink, Hossain H. Saneii, Heinrich J. Schostarez, Donald T. Pals
  • Patent number: 4880777
    Abstract: Disclosed are novel polypeptides selected from the group consisting of: ##STR1## functional equivalents thereof: and organic and inorganic addition salts thereof; and ##STR2## functional equivalents thereof:and organic and inorganic addition salts thereof.These polypeptides have been found to promote the release and elevation of growth hormone levels in the blood of animals. Also disclosed are novel combinations of said polypeptides with other polypeptides, novel formulations including said polypeptides as well as methods for administering said polypeptides, alone and in combination with other polypeptides acting in a synergistic manner to promote release and elevation of growth hormone levels in animals.
    Type: Grant
    Filed: September 1, 1987
    Date of Patent: November 14, 1989
    Assignee: Eastman Kodak Company
    Inventor: Frank A. Momany
  • Patent number: 4880780
    Abstract: The invention discloses a series of difluoroketone, mono- di- and tri-peptide derivatives of formula Ia, Ib and Ic:______________________________________ (Formula set out on pages following Examples) Ia (Formula set out on pages following Examples) Ib (Formula set out on pages following Examples) Ic ______________________________________and salts thereof where appropriate, and wherein the radicals are defined hereafter in the specification. The derivatives are useful in inhibiting the action of human leukocyte elastase. There are also disclosed methods and intermediates for the manufacture of, and pharmaceutical compositions comprising, the said derivatives.
    Type: Grant
    Filed: June 4, 1987
    Date of Patent: November 14, 1989
    Assignee: ICI Americas Inc.
    Inventors: Diane A. Trainor, Mark M. Stein
  • Patent number: 4880619
    Abstract: Oral compositions such as mouthwashes and toothpastes, creams, gels and powders containing as anticalculus agent phosphonoformic acid or salt thereof and optionally also an F-providing anticaries compound, and method of using such compositions.
    Type: Grant
    Filed: May 2, 1986
    Date of Patent: November 14, 1989
    Assignee: Colgate-Palmolive Company
    Inventor: Abdul Gaffar
  • Patent number: 4879273
    Abstract: Glucagon analogs characterized principally by deletion of the number one histidine and replacement of the number nine aspartic acid with glutamic acid are useful adjuncts to insulin therapy.
    Type: Grant
    Filed: May 22, 1987
    Date of Patent: November 7, 1989
    Assignee: The Rockefeller University
    Inventor: Robert B. Merrifield
  • Patent number: 4879370
    Abstract: Substantially pure alkyl monoesters of glutathione, the ester being of the glycine carboxylic acid, and use thereof to increase cellular levels of glutathione.
    Type: Grant
    Filed: July 27, 1988
    Date of Patent: November 7, 1989
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Alton Meister
  • Patent number: 4877785
    Abstract: Non-peptidyl compounds characterized generally as .beta.-succinamidoacyl aminodios are useful as renin inhibitors for the treatment of hypertension.
    Type: Grant
    Filed: October 1, 1987
    Date of Patent: October 31, 1989
    Assignee: G. D. Searle & Co.
    Inventors: Gunnar J. Hanson, John S. Baran
  • Patent number: 4877770
    Abstract: Derivatives of GHL-Cu possessing greater resistance to proteolytic enzyme breakdown are disclosed. These derivatives can be taliored to increase their fat solubility, making them more useful in the formation of pharmaceutical creams and gels. Further, the derivatives of the present invention possess significant superoxide dismustase activity, making them useful for enhancing the wound-healing process in animals.
    Type: Grant
    Filed: February 17, 1989
    Date of Patent: October 31, 1989
    Assignee: ProCyte Corporation
    Inventor: Loren R. Pickart
  • Patent number: 4877602
    Abstract: A transparent dentifrice is provided wherein a cellulose derivative, typically CMC-Na, having a viscosity of 5 to 20 centipoises measured as 1% aqueous solution at 25.degree. C. is blended as a binding agent.
    Type: Grant
    Filed: November 17, 1987
    Date of Patent: October 31, 1989
    Assignee: Lion Corporation
    Inventors: Michio Uematsu, Nobuo Suganuma
  • Patent number: 4876244
    Abstract: The present invention relates to a stable medical composition for injection containing (1) a Spergualin of the formula: ##STR1## [wherein R is ##STR2## (wherein R' is a lower alkyl group having 1 to 4 carbon atoms), ##STR3## or a salt thereof and (2) at least one stabilizer selected from the group consisting of mannitol, maltose, dextran, lactose, cyclodextrin, gelatin, chondroitin sulfate, and human serum albumin; when R is ##STR4## mannitol is excepted. A spergualin is useful as cancer control agents and immunomodulators.
    Type: Grant
    Filed: August 11, 1987
    Date of Patent: October 24, 1989
    Assignee: Zaidan Hojin Biseibutsu Kagaku
    Inventors: Hamao Umezawa, Shintaro Suzuki, Taka'aki Ohkuma, Fumihiro Sato, Teruya Nakamura
  • Patent number: 4876243
    Abstract: Vasopressin-like peptide whose structures have been modified by an alpha-methyl amino acid at the 4 or 7 position are set forth. These compounds have potent vasopressin antagonist activities.
    Type: Grant
    Filed: August 27, 1987
    Date of Patent: October 24, 1989
    Assignee: Smithkline Beckman Corporation
    Inventors: Garland R. Marshall, Michael L. Moore
  • Patent number: 4876242
    Abstract: A synthetic gene encoding a 71-amino acid analog of human insulin-like grouwth factor (hIGF-I) has been constructed and expressed in the yeast, Saccharomyces cerevisiae. The protein analog, IGF132, contains the first 17 amino acids of the B chain of human insulin in place of the first 16 amino acids of hIGF-I. The purified hybrid protein has high affinity for the type I IGF recepto (12 nM) yet has drastically reduced affinity for human serum carrier proteins (>1000 nM). This analog is 5 to 10 times more active than normal hIGF-I in stimulating DNA synthesis in 3T3 cells and is a more active growth factor in vivo due to its reduced affinity for serum carrier proteins. Other proteins with similar properties have also been constructed.
    Type: Grant
    Filed: September 21, 1987
    Date of Patent: October 24, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Joy D. Applebaum, Marvin L. Bayne, Margaret A. Cascieri
  • Patent number: 4874743
    Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human phospholipase inhibitor-like polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human phospholipase inhibitor-like polypeptide. In appropriate hosts these DNA sequences permit the production of human phospholipase inhibitor-like polypeptides useful as anti-inflammatory agents and methods in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases as well as other disorders involving inflammatory processes.
    Type: Grant
    Filed: March 15, 1985
    Date of Patent: October 17, 1989
    Assignee: Biogen, Inc.
    Inventors: Barbara P. Wallner, R. Blake Pepinsky, Jeffrey L. Garwin
  • Patent number: 4874608
    Abstract: A method is described for treating mammalian solid tumors by administering leukocyte-derived amplifiers of the immune system to tumor-bearing subjects. The amplifiers include Beta-1.0, Beta-1.1, Beta-1,12, TG, and TGG.
    Type: Grant
    Filed: April 27, 1987
    Date of Patent: October 17, 1989
    Assignee: Imreg, Inc.
    Inventor: A. Arthur Gottlieb
  • Patent number: 4874745
    Abstract: A phenyl derivative of pepstatin A, which is much more potent than pepstatin in inhibiting renin enzyme activity and has significantly greater selectivity for renin over pepsin inhibition than does pepstatin, which is useful in treating hypertension and congestive heart failure.
    Type: Grant
    Filed: October 1, 1987
    Date of Patent: October 17, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Leeyuan Huang, Lawrence Koupal, Joseph Dunn, Jr., Jerrold M. Liesch, Otto Hensens, H. Boyd Woodruff
  • Patent number: 4874844
    Abstract: The tripeptide Arg-Lys-Glu, synthetized by conventional solution methods, and its salts display immunostimulating activity both on maturation of immature T cells and on T cell function.
    Type: Grant
    Filed: April 6, 1987
    Date of Patent: October 17, 1989
    Assignee: Ellem Industria Farmaceutica S.p.A.
    Inventors: Brunetto Brunetti, Marco Prada